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Radiation-induced alternative 
transcription and splicing events 
and their applicability to practical 
biodosimetry
Ellina Macaeva1,2, Yvan Saeys3,4, Kevin Tabury1, Ann Janssen1, Arlette Michaux1, 
Mohammed A. Benotmane1, Winnok H. De Vos2,5, Sarah Baatout1,2 & Roel Quintens1
Accurate assessment of the individual exposure dose based on easily accessible samples (e.g. blood) 
immediately following a radiological accident is crucial. We aimed at developing a robust transcription-
based signature for biodosimetry from human peripheral blood mononuclear cells irradiated with 
different doses of X-rays (0.1 and 1.0 Gy) at a dose rate of 0.26 Gy/min. Genome-wide radiation-induced 
changes in mRNA expression were evaluated at both gene and exon level. Using exon-specific qRT-PCR, 
we confirmed that several biomarker genes are alternatively spliced or transcribed after irradiation 
and that different exons of these genes exhibit significantly different levels of induction. Moreover, a 
significant number of radiation-responsive genes were found to be genomic neighbors. Using three 
different classification models we found that gene and exon signatures performed equally well on dose 
prediction, as long as more than 10 features are included. Together, our results highlight the necessity 
of evaluating gene expression at the level of single exons for radiation biodosimetry in particular and 
transcriptional biomarker research in general. This approach is especially advisable for practical gene 
expression-based biodosimetry, for which primer- or probe-based techniques would be the method of 
choice.
The recent nuclear accident at Fukushima Daiichi in March 2011 and the subsequent growing concerns about 
large-scale human radiation exposure have triggered the widespread recognition that there is an urgent need for 
effective biodosimetry tools that are capable of confirming or quantifying exposure to radiation in large cohorts 
of individuals potentially exposed to unknown doses for triage and personalized treatment1.
Following the Fukushima accident, the only individuals who received effective radiation doses of over 100 
mSv, were 173 emergency and mitigation workers. Despite this generally low radiation exposure, which was 
clearly below the threshold of acute radiation disease, about 90,000 people were evacuated as a preventive safety 
action. This measure reduced the levels of possible exposure but also resulted in a number of evacuation-related 
deaths due to stress and/or lack of medical and social welfare facilities2. Hence, a rapid and accurate biodosimetry 
method would reduce the uncertainty about received doses and may mitigate psychological and health problems 
related to additional stress among the individuals who may or may have not been exposed to radiation (the 
so-called “worried wells”)3,4.
Cytogenetic measurements, more specifically dicentric assays, are considered the gold standard in biodo-
simetry5. While reliable and applicable to assess doses as low as 100 mGy, this method is time-consuming and 
laborious, and is not amenable to rapid diagnostics. A promising alternative technique consists in using gene 
expression data. Indeed, experimental data obtained by means of microarrays6, quantitative nuclease protection 
assay7, NanoString technology8, quantitative PCR (qPCR)9, or chemical ligation-dependent probe amplification 
(CLPA) assay10 have proven most efficient in accurately and rapidly assessing radiation exposure.
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Several recent studies have shown that transcriptome analysis at the individual exon level may significantly 
add to our understanding of the transcriptional response to radiation exposure11–13. In particular, alternative 
transcription and alternative pre-mRNA splicing dramatically expand the translational repertoire. We hypothe-
sise that alternative transcription and splicing analyses applied in the context of radiation exposure may generate 
additional radiation biomarkers with potentially increased sensitivity.
To test our hypothesis, we established gene and exon signatures that may serve as radiation biomarkers and 
subsequently compared their reliability and effectiveness. We opted for two X-ray doses relevant for triage pur-
poses (0.1 and 1.0 Gy) and compared these to sham-irradiated control samples. We evaluated the predictive per-
formance of gene and exon signatures using three different statistical models, which were further used to assess 
the robustness of our gene signature on an independent, publicly available dataset (Fig. 1). Our results yield new 
insights into transcriptional biomarker identification studies using genome-wide strategies and underline the 
importance of investigating gene expression at the single exon level.
Results
Low- and high-dose X-irradiation results in up-regulation of common genes. Whole-genome 
microarrays were used to analyse genome-wide transcriptional changes in human peripheral blood mononuclear 
cells (PBMCs) at 8 h after exposure to X-ray doses of 0.1 and 1.0 Gy compared to sham-irradiated control cells. 
Three-way ANOVA revealed 125 significantly differentially expressed genes (FDR < 0.05) between different doses 
of X-rays (Supplementary Table S1). Of these, the large majority (90.4%) were dose-dependently induced (Pearson’s 
correlation coefficients in Supplementary Table S1). Gene expression changes in response to radiation expo-
sure were not gender-dependent (column FDR-corrected p-value (Dose*Gender) in Supplementary Table S1), 
as also previously suggested14. Unsupervised hierarchical clustering yielded a clear separation of the samples 
depending on the exposure dose (except for 3 out of 20 low dose-irradiated samples, which clustered together 
with the control samples) (Fig. 2a). Similar results were obtained using principal component analysis (PCA) 
of the same dataset (Fig. 2b). Comparison of the controls with each of the different doses yielded significantly 
increased expression levels following exposure to 0.1 Gy in 23 genes. Of these, 20 genes (87%) were also differen-
tially expressed in cells irradiated with 1.0 Gy (Fig. 2c). Unsupervised hierarchical clustering using this subset of 
overlapping genes resulted in a perfect separation of the samples by exposure dose (Fig. 2d).
X-irradiation induces alternative transcription and splicing. Considering the well-documented 
ability of ionising radiation to induce alternative gene splicing/transcription11,15, we first performed an 
Alternative Splicing ANOVA to identify which genes produced alternative transcripts following X-ray irradiation 
Figure 1. Outline of the strategy to identify gene and exon signatures suitable for prediction of exposure 
to doses of 0.1 and 1.0 Gy of X-rays. Isolated PBMCs from 10 healthy donors were irradiated and RNA 
was extracted 8 h after irradiation. RNA was hybridised onto Affymetrix Human Gene 1.0 ST arrays and 
differentially expressed and alternatively spliced genes were identified and validated using qRT-PCR. Three 
classification algorithms were employed to identify predictive gene and exon signatures and their predictive 
performance was tested using 2-fold cross-validation (boxes labeled with letters A–J represent all the samples 
from each out of ten donors (0.0, 0.1 and 1.0 Gy, in duplicates). The best performing gene signature as identified 
by the RF model was further evaluated on an independent, publicly available dataset.
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(Supplementary Table S2). Our results were in accordance with those of Sprung and co-authors11 for the most sig-
nificant genes, despite differences in experimental models (e.g. PBMCs versus lymphoblastoid cell lines) and con-
ditions (doses, time points and gene expression platforms). The Splice Index algorithm with additional filtering 
identified much less alternatively spliced genes (3 genes after 0.1 Gy exposure and 17 after 1.0 Gy) (Supplementary 
Table S3). The FIRMA algorithm results were in keeping with those obtained by the Splice Index (37 genes after 
0.1 Gy exposure and 39 after 1.0 Gy) (Supplementary Table S4) with 15 genes being identified as alternatively 
spliced in response to 1.0 Gy by both algorithms. The same 15 genes were also identified as highly significant 
by the Partek Alternative Splicing ANOVA algorithm, with 13 of them among the 30 most significant ones 
according to their p-values (Supplementary Table S2) and, importantly, all 15 genes were differentially expressed 
(Supplementary Table S1). It has been shown before that radiation-induced alternative splicing occurs predomi-
nantly in genes that are differentially expressed at the gene level11,13.
Although it is not possible to infer the exact sequence identities of specific transcript variants from the gene 
array results, it was clear that different alternative splicing and transcription mechanisms had been activated in 
response to radiation exposure. For example, we found evidence of transcription from alternative promoters 
(e.g. ASTN2, NDUFAF6, FDXR and PCNA), alternative transcription initiation (e.g. ASTN2), alternative splicing 
(e.g. ASTN2 and FDXR), and use of alternative 3′ -UTRs (e.g. ASTN2) (Fig. 3a–d and Supplementary Figure S1). 
Figure 2. Gene expression changes in PBMCs in response to irradiation at 8 h after exposure. In total,  
125 genes were identified as differentially expressed by ANOVA (FDR corrected p-values < 0.05) between 
0.1 Gy and 1.0 Gy samples and sham-irradiated controls. (a) Unsupervised hierarchical clustering analysis 
of these 125 genes (rows) showed good separation of samples (columns) depending on the dose of exposure. 
Red: high gene expression, blue: low gene expression. (b) 2D Principal Components Analysis (PCA) also 
separated samples depending on the dose. Each circle represents the expression profile of the 125 significantly 
differentially expressed genes in one sample. The percentage of the variance explained by the first and the 
second principal components is 44.7% and 6.58%, respectively. Ellipses represent two standard deviations. (c) 
Venn diagram showing the overlap of differentially expressed genes after exposure to 0.1 and 1.0 Gy of X-rays. 
(d) Unsupervised hierarchical clustering analysis of the 20 overlapping genes showed perfect separation of 
samples depending on the dose of exposure. Red: high gene expression, blue: low gene expression.
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The observed variation in the expression levels between different transcripts was validated by qRT-PCR using 
transcript-specific primers (Fig. 3). We found significant differences in radiation-induced expression of different 
variants of ASTN2 (Fig. 3a), FDXR (Fig. 3c) and PCNA (Fig. 3d) at 8 h after exposure to 0.1 and 1.0 Gy, while this 
difference was not significant for NDUFAF6 after exposure to 1.0 Gy, possibly because of large interindividual 
variations in the transcriptional response of this gene (Fig. 3b).
Furthermore, several of the probe sets among the 125 genes that were differentially expressed (Supplementary 
Table S1) have not yet been annotated to a gene. Mapping of their sequences to the mouse genome showed that 
most of them hybridise to intronic sequences of PVT1, EI24, REV3L, RNGTT and ITPR2 (Supplementary Figure 
S2). Two other probe sets were found to map to a sequence downstream of PCNA and upstream of REV3L, 
respectively. Interestingly, EI24, REV3L, ITPR2 and PCNA were among the identified radiation-responsive genes 
(Supplementary Table S1), whereas Pvt1 was recently identified as a radiation-responsive gene in the embryonic 
mouse brain13. Our data therefore suggest that these probe sets actually identify currently unknown exons of 
these radiation-responsive genes.
Radiation exposure induces expression of neighboring genes. The above results indicate that 
although radiation exposure leads to exon skipping and the use of alternative splice junctions, the mechanism 
that was most often observed to result in transcript variation was the expression of transcripts from alterna-
tive promoters. Since most of these genes are regulated by p53, we hypothesise that the DNA damage response, 
which is activated after irradiation, induces the expression of p53-dependent transcript variants, as shown pre-
viously in both lymphoblastoid cell lines11 and the embryonic mouse brain13. Interestingly, we also observed that 
a significant proportion (23 out of 129 annotated genes; 17.8%) of the genes that were differentially expressed 
after irradiation with 1.0 Gy are genomic neighbors, several of which are transcribed from bidirectional pro-
moters (Supplementary Figure S3). This finding aligns well with a study in which human lung fibroblasts were 
treated with the p53 activator 5-fluorouracil16. Chromatin immunoprecipitation with a p53 antibody followed by 
next-generation sequencing revealed that about 4% of the high-confidence peaks were located at bidirectional 
promoters16, including some that are identical to those observed by us (e.g. FAS-ACTA2 and ASTN2-TRIM32).
Differential expression of distinct exons is more pronounced compared to entire genes. For 
several genes, individual exons responded much stronger to the irradiation than others. This suggested that sig-
natures of highly responsive exons might be more sensitive and would have greater predictive value as a bio-
marker of radiation exposure compared to genes, whose expression signals are averaged over the totality of their 
exons. This observation led us to perform ANOVA at the exon level as well, revealing 706 differentially expressed 
exons (FDR < 0.05) between different doses of radiation exposure (Supplementary Table S5), with 157 exons 
being differentially expressed after exposure to both 0.1 and 1.0 Gy (Supplementary Table S6). Comparison of 
the distributions of fold changes in expression between genes and exons confirmed that the changes in the exon 
expression levels were more pronounced compared to the genes on a generic basis, especially at the higher dose 
of 1.0 Gy (Fig. 4a,b). Average fold changes for significant genes and exons after exposure to 0.1 Gy were 1.58 and 
1.71, respectively (Fig. 4c), increasing to 1.72 and 2.21 after exposure to 1.0 Gy (Fig. 4d). Clustering of the samples 
based on the expression levels of the 706 differentially expressed exons using unsupervised hierarchical clustering 
(Fig. 5a) and PCA (Fig. 5b) resulted in perfect separation of the samples according to radiation dose. Together, 
these results suggest that exons might be more sensitive radiation biomarkers.
Prediction analysis of transcriptional markers for radiation exposure. To identify signatures of genes 
and exons that distinguish between different irradiation doses, we used three supervised classification models: 
generalised linear models (GLM), Random Forests (RF) and Nearest Shrunken Centroids as implemented 
by the PAM (Prediction Analysis for Microarrays) algorithm. Additionally, we assessed the suitability of the 
above-mentioned models for classification of the samples according to exposure dose.
Table 1 shows the results of all models for gene and exon level analysis in the 2-fold cross-validation setting. 
Both PAM and the RF models attained a very high performance even with a small number of features, and both 
models outperformed the GLM model. A combined PAM-RF model (features selected by PAM combined with 
classification by RF) achieved perfect classification with only two gene features (Table 1).
Similar results were obtained for classification at the exon level (Table 1). Here, the PAM and RF models out-
performed the GLM model more clearly. Comparison between exon and gene level analysis gave slightly inferior 
results for exons, with more features being needed to obtain optimal predictive performance. On the other hand, 
exons performed better than genes when 100 or all features were used. The genes/exons that were selected as the 
top 20 most important features for each of the classifiers are listed in Table 2. Of these, 12 genes were identified as 
differentially expressed according to ANOVA and suitable for class prediction by both RF and PAM (AEN, BAX, 
DDB2, EDA2R, FDXR, MDM2, POLH, RPS27L, SESN1, TNFRSF10B, XPC, ZMAT3).
To evaluate the robustness of gene expression signatures for practical radiation biodosimetry, we tested the 
predictive performance of our signature on an independent dataset from a study in which whole blood samples 
from male and female smokers and non-smokers were irradiated with similar doses to those used in our study, 
i.e., 0.1 Gy, 0.5 Gy and 2.0 Gy14. Using ten of our best predictive markers, we were able to classify these independ-
ent samples with 97% accuracy (Fig. 6a), which overall is similar to the accuracy obtained in the original publi-
cation14. Next, we ran the RF model on the dataset of Paul and Amundson, and used the ten best predictors for 
cross-validation on our samples. This resulted in 100% accuracy (Fig. 6b), i.e., identical to what we found using 
our 10 best gene predictors (Table 1). Unfortunately, we were not able to independently validate our exon signa-
tures because this dataset did not contain exon-level information.
Furthermore, we compared our results with those of three other studies in which different subjects, radiation 
doses (up to 8 Gy), dose rates, radiation qualities, time points, cell types and gene expression platforms were 
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Figure 3. Radiation-induced alternative splicing. (a–d). Upper panels show genomic organisation of a few 
transcript variants from the UCSC database of ASTN2 (a), NDUFAF6 (b), FDXR (c) and PCNA (d). Each blue 
box represents an exon and the interconnecting lines represent introns. Lower panels show the log2 normalised 
intensity signals for each microarray probe, located on each specific exon shown above (error bars were left out 
to increase clarity). Arrows indicate the location of the primer pairs (pp) used for qRT-PCR validation. qRT-
PCR validation results for each primer pair are shown on the right. Graphs represent  
mean + standard deviation. Statistical comparison was performed using the paired t-test (*p-value < 0.05,  
**p-value < 0.005, ***p-value < 0.0001, ns: not significant).
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used. The specific characteristics of these studies are listed in Supplementary Table S7. Our comparative analysis 
revealed a very high degree of overlap in radiation-responsive genes between the different experiments, especially 
between those in which peripheral blood or PBMCs were used (Fig. 6c). Nevertheless, 27 out of 79 genes (34%) 
Figure 4. Fold-change induction of exon expression is more pronounced compared to gene expression. 
(a,b) Cumulative distributions of fold changes in expression for significantly differentially expressed genes and 
exons after exposure to 0.1 Gy (a) and 1.0 Gy (b) of X-rays. p-values for the difference between distributions 
for genes and exons according to the Kolmogorov-Smirnov test were 0.195 and 0.000 for 0.1 Gy and 1.0 Gy, 
respectively. (c,d) Box plots depicting fold changes in expression for the same data as in (a,b). (c) Genes and 
exons upregulated at 0.1 Gy. (d) Genes and exons upregulated at 1.0 Gy. Centerlines show the median, boxes 
represent the range between the first and third quartiles and whiskers represent the highest and lowest values. 
***p-value < 0.0001 (Two-tailed Mann-Whitney test).
Figure 5. Probe (exon) expression changes in PBMCs in response to irradiation. In total, 706 exons were 
identified as differentially expressed by ANOVA (FDR corrected p-values < 0.05) between different irradiation 
doses. (a) Unsupervised hierarchical clustering analysis of the 706 exons (rows) showed perfect separation of 
samples (columns) depending on the dose of exposure. Red: high gene expression, blue: low gene expression. 
(b) 2D Principal Components Analysis (PCA) also separated samples depending on the dose. Each circle 
represents the expression profile of the 706 significantly differentially expressed exons in one sample. The 
percentage of the variance explained by the first and the second principal components is 45.9% and 7.3%, 
respectively. Ellipses represent two standard deviations.
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that were found to be radiation-responsive in keratinocytes and fibroblasts17 were also identified in at least two 
other studies (Fig. 6c).
Together, these results hint at the existence of a core signature of genes that may be applicable for radiation 
biodosimetry for a wide range of doses, dose rates, and cell types/specimens after exposure to different radiation 
qualities.
Validation of gene and exon expression using qRT-PCR. qRT-PCR was used to validate the expres-
sion changes of several identified biomarker genes in PBMCs and whole blood. In general, the majority of the 
examined genes showed a dose-dependent up-regulation (Pearson’s correlation coefficients ranging between 0.82 
and 0.99) after X-irradiation (Fig. 7), although clear differences in the transcriptional response were observed 
between different genes. For example, most of the tested genes (ASTN2, MDM2, NDUFAF6, POLH, TNFRSF10B) 
showed a 2- to 3-fold induction in expression at 8 h after exposure to 1.0 Gy of X-rays, while DDB2, PCNA and 
FDXR expression levels were 4-, 5- and 25-fold induced, respectively. Furthermore, most of these genes showed 
significant differences in expression at 8 h after exposure to a dose of 0.1 Gy, demonstrating their sensitivity for 
this radiation dose at this time point.
To confirm the obtained results, we also assessed the expression levels of these genes at a later time point, 
i.e. 24 h following irradiation. Our results point to differences in the kinetics of the transcriptional response of 
these radiation-induced genes: reduced expression levels – but no complete return to basal expression levels - 
for FDXR, similar expression levels for DDB2, MDM2, PCNA, POLH and TNFRSF10B, and further increased 
expression levels for ASTN2 and NDUFAF6 after 24 h compared to 8 h (Fig. 7). In many cases, however, statistical 
significance of expression changes after exposure to 0.1 Gy was lost after 24 h.
Model
2 5 10 20 50 100 ALL
G E G E G E G E G E G E G E
GLM Net 0.985 0.942** 0.965 0.926** 0.932 0.922** 0.949 0.946 0.953 0.952 0.952 0.951** 0.959 0.953
RF 0.985 0.968** 0.998 0.993** 1.000 0.998** 1.000 1.000 1.000 1.000 1.000 1.000** 0.918 0.955
PAM 0.999 0.997 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 0.997 1.000** 0.999 1.000**
PAM + RF 1.000 0.997 1.000 0.999 1.000 1.000 1.000 1.000 1.000 0.999** 1.000 1.000 0.917 0.953
Table 1.  Predictive performance at gene (G) and exon (E) levels using 2, 5, 10, 20, 50, 100 or all features 
as measured by the AUC. GLM: Generalized Linear Models; RF: Random Forests; PAM: Nearest Shrunken 
Centroids. **p < 0.01 for comparison between gene and exon level (Mann-Whitney U-test).
Random Forests PAM
Genes Exons Genes Exons
1. DDB2 ASCC3 exon 43 (8128473) DDB2 DDB2 exon 4 (7939743)
2. POLH DDB2 exon 5 (7939744) POLH DDB2 exon 5 (7939744)
3. AEN XPC exon 15 (8085487) MDM2 FDXR exon 8 (8018242)
4. TNFRSF10B TNFRSF10B exon 9 (8149735) TNFRSF10B DDB2 exon 8 (7939747)
5. RPS27L RPS27L exon 1 (7989499) RPS27L POLH exon 5 (8119864)
6. FDXR PCNA exon 2 (8064851) AEN AEN exon 3 (7985775)
7. MDM2 XPC exon 2 (8085501) PCNA TNFRSF10B exon 9 (8149737)
8. ZMAT3 ASCC3 exon 41 (8128476) XPC POLH exon 11 (8119870)
9. XPC ASCC3 exon 6 (8128513) ASCC3 DDB2 exon 3 (7939742)
10. C12orf5 POLH exon 11 (8119871) ZMAT3 RPS27L exon 3 (7989497)
11. EDA2R ASCC3 exon 14 (8128504) GADD45A MDM2 exon 4 (7956994)
12. NUP133 POLH exon 10 (8119869) SESN1 DDB2 exon 9 (7939748)
13. FBXO22 MDM2 exon 10 (7957001) C12orf5 POLH exon 4 (8119863)
14. GADD45A POLH exon 1 (8119860) EDA2R MDM2 exon 7 (7956997)
15. ZNF79 RPS27L exon 2 (7989498) FDXR DDB2 exon 6 (7939745)
16. BAX TNFRSF10B exon 7 (8149739) CCNG1 POLH exon 10 (8119869)
17. SESN1 ASCC3 exon 13 (8128505) BAX PCNA exon 3 (8064850)
18. ACTA2 TNFRSF10B exon 5 (8149756) PPM1D TNFRSF10B exon 9 (8149735)
19. ITGA2 PHPT1 exon 2 (8159444) FAS NDUFAF6 exon 2 (8147426)
20. TMEM30A ASCC3 exon 37 (8128481) PAPPA-AS1 DDB2 exon 7 (7939746)
Table 2. Top 20 most important features selected by PAM and Random Forests models for the data at gene 
and exon level. Features are listed according to their internal weight (importance) in every model. The numbers 
in brackets in the Exons columns indicate corresponding Affymetrix Probe set IDs. Overlapping genes and 
exons are indicated in bold.
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In addition, we performed a similar qRT-PCR validation experiment using whole blood samples exposed to 
the same doses. Overall, the obtained results were very similar to those observed in PBMCs (Fig. 7), demonstrat-
ing that PBMCs are a suitable model for the transcriptional radiation response of whole blood.
Discussion
Prompted by the rapid development of high-throughput genomic profiling technologies, several groups 
have explored the potential of gene expression signatures as biomarkers of (low dose) exposure to ionising 
radiation6,8,18–22. Most of the genes identified in these studies are known to be regulated by p53 and 
are involved in cell cycle regulation, DNA damage repair and apoptosis and some are already induced 
after exposure to doses as low as 5–25 mGy9,22–24. Furthermore, some of these genes allow to dis-
criminate between ionising radiation response profiles and those induced by inflammation25. Several 
genome-wide studies have been undertaken to assess the in vivo transcriptional response to ionis-
ing radiation using blood samples from radiotherapy patients undergoing either total body irradi-
ation26 or local intensity modulated radiotherapy27. The results of these investigations indicate that 
in vivo irradiation mainly affects genes involved in pathways that are related to the immune system and inflamma-
tory responses, as well as p53-mediated pathways. Accordingly, induction of p53-dependent genes was observed 
in patients either undergoing CT scans (up to 4.3 cGy) or receiving (F-18)-fluoro-2-deoxy-d-glucose (0.6 cGy)24. 
Overall, the examined genes were induced in all samples, although differences in the in vivo and in vitro response 
were found, especially for doses below 5 cGy24. Other studies have identified in vitro gene signatures that could 
accurately predict the in vivo radiation exposure status10,28,29. Overall, these studies have shown that the in vitro 
transcriptional radiation response is a reliable model for the in vivo situation. Another possibility for biodosime-
try studies is the use of animal models. For instance, it was demonstrated that radiation-responsive genes in mice 
show a response that is similar to that of homologous genes from ex vivo human studies20,28,30. On the other hand, 
gene expression profiles developed through analysis of murine blood radiation responses alone were found to be 
inaccurate in predicting human radiation exposures10.
Unlike the moderate to high radiation doses used in most other studies dealing with transcriptional radiation 
biomarkers, the X-ray doses applied in this study are low to moderate but nonetheless relevant for medical triage. 
The moderate dose of 1.0 Gy represents the lower limit of doses that result in acute radiation syndrome31 and is 
associated with a high probability of long-term stochastic health effects. The low dose of 0.1 Gy is not associated 
with any acute health effects but might require medical follow-up since the risk of long-term effects, particularly 
cancer, cannot be excluded32. To the best of our knowledge, only two studies aimed at identifying a predictive gene 
signature based on genome-wide data have used doses of 0.1 Gy or below14,22. However, no cross-validation at the 
individual donor level was performed in either of these studies, which may have positively biased the results.
One of the initial steps in our study consisted in a gene-level analysis of the microarray data, resulting in a list 
of genes capable of discriminating between the exposure conditions with high accuracy. A substantial fraction 
of the radiation-responsive genes were located in close physical proximity on the genome (often as neighbors 
with bidirectional promoters). We propose that these genes are co-regulated, most likely via activation by p53, 
or via chromatin loops which can bring promoters in close proximity, thereby exposing them to the same reg-
ulatory proteins. This co-regulation may be related to the nature of the stress inflicted on the cells by radiation 
exposure (i.e. DNA damage) since the frequency of bidirectional promoters is enriched in DNA repair genes 
compared to other gene classes33,34. This observation may also be instrumental in identifying currently undis-
covered radiation-responsive transcripts. One such new gene we identified as a predictive marker is PAPPA-AS1 
Figure 6. Gene signatures are robust predictive biomarkers of exposure to radiation. (a) Five-fold cross-
validation of our 10 best predictive genes on the dataset of Paul and Amundson14 resulted in 97% accuracy 
for sample classification. (b) Five-fold cross-validation of the 10 best predictive genes from the dataset of Paul 
and Amundson14 as identified by the Random Forests model resulted in 100% accuracy for classification of 
our samples. (c) Overlap between differentially expressed genes from this study and gene signatures identified 
by Paul and Amundson6, Chauhan and co-authors18 and Warters and co-authors17. Common genes between 
all datasets are DDB2, POLH, MDM2, RPS27L, FDXR, CCNG1, TRIAP1, SESN1, FBXO22, PPM1D, ANKRA2, 
CDKN1A, TRIM22, and BBC3.
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(Table 2), which is a long non-coding RNA transcribed from the opposite strand of PAPPA, presumably from a 
shared bidirectional promoter with ASTN2.
The specific microarray platform we used, interrogates the vast majority of exons from multi-exon genes, 
allowing to analyse the expression data at the exon level as well. Although we could not draw definite conclusions 
about the exact mechanisms underlying these events, our data are suggestive of the activation of different alter-
native splicing mechanisms (exon skipping, alternative splice sites, alternative polyadenylation) in response to 
irradiation. However, the most utilised mechanism appeared to be alternative promoter usage. Importantly, such 
events result in significant differences in the expression of single exons, while changes in the expression of the 
gene itself are less pronounced. Forrester and Sprung proposed that dose prediction could be improved by the use 
of radiation-responsive transcript variants as biomarkers in combination with unresponsive intragenic controls35. 
However, these authors evaluated only three genes, one of which turned out unsuitable for dose prediction35.
To the best of our knowledge, comparison of gene and exon signatures for class prediction is a novel approach 
in biodosimetry, and has only rarely been applied in general biomarker research. Tian et al. showed that exons 
outperformed genes as biomarkers of Tourette syndrome36. In another study, gene and exon signatures performed 
equally well in predicting overall survival in neuroblastoma patients37. Likewise, our results are indicative of an 
overall comparable prediction performance of gene and exon signatures.
From our results, and those from other groups6,14,18–22, it is now clear that there is a core of approximately 
20 genes that can be regarded as robust biomarkers for radiation exposure to a wide range of doses. As such, 
genome-wide expression studies are undoubtedly highly informative to identify accurate dose-prediction sig-
natures. Nevertheless, using microarrays for mass casualty screening in a radiological emergency situation is 
not a very realistic approach, due to high costs, limited availability of infrastructures equipped for performing 
these assays, the rather long response time and the complexity of the analysis. A more cost- and time-efficient 
alternative would be to use primer- or probe-based assays (such as qRT-PCR) that measure the expression of a 
Figure 7. qRT-PCR validation of the microarray results. qRT-PCR results for ASTN2, NDUFAF6, FDXR, 
PCNA, POLH , TNFRSF10B, MDM2 and DDB2 genes at 8 and 24 h after irradiation of PBMCs and whole blood. 
Graphs represent mean + standard deviation. Statistical comparison was performed using the paired t-test 
(*p-value < 0.05, **p-value < 0.005, ***p-value < 0.0001).
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limited number of a priori identified biomarkers. However, these methods, in contrast to exon-specific microar-
rays, do not allow to measure the expression of the entire gene but only cover a relatively short region of one or a 
few exons. Therefore, selection of the most appropriate exons is an imperative prerequisite for using primer- or 
probe-based assays. We validated the expression profiles of some of the identified genes that were also alterna-
tively spliced in response to irradiation by qRT-PCR using variant- and exon-specific primers for transcripts with 
different radiation responses, and, for many of the tested genes, we only found a significant difference in expres-
sion in low dose-exposed samples with primer pairs amplifying the most sensitive exons. This suggests that these 
exons may be more sensitive markers for prediction of similar low doses and possibly also those below 0.1 Gy, 
i.e., doses at which combined exon signals (i.e. gene level) may be no longer predictive. This further highlights 
the importance of always obtaining prior knowledge about expression levels at the exon level when primer- or 
probe-based assays are used to perform “gene-level” expression analysis.
Our study has a few limitations. First, only two radiation doses and one time point after irradiation were used 
to identify the predictive signatures. However, a comparative analysis with previously published studies, as well as 
validation of the predictive performance of our signatures on an independent dataset containing two additional 
doses, revealed that our signature also applies to higher doses and longer time points. Second, the gene expres-
sion profiles applied in our study stemmed from isolated PBMCs and not from whole blood. To address this, we 
validated gene expression using qRT-PCR on ex vivo irradiated blood samples, revealing highly similar transcrip-
tional responses to radiation in PBMCs and whole blood for the investigated genes.
In conclusion, we have shown that gene and exon signatures are equally performing in predicting exposure 
to radiation doses within the 0.1–1.0 Gy range at 8 h after exposure. We have generated a robust fingerprint for 
predictive biodosimetry and especially triage of individual radiation casualties. Implementation of a dedicated 
assay based on the identified biodosimetric panel may lead to improved point-of-care diagnostics for radiological 
accidents. Finally, we have shown the importance of evaluating gene expression at the level of single exons for 
transcriptional biomarker discovery in general.
Methods
Experimental procedures are schematically summarised in Fig. 1.
Blood collection and PBMCs isolation. Peripheral blood samples used for microarrays were collected 
from 10 healthy, non-smoking Caucasian donors (5 males/5 females; age range: 23–50 years; median age: 28 years) 
in EDTA vacutainer tubes. All procedures followed were approved by the local SCK•CEN Ethics Committee and 
were carried out in accordance with the ethical standards of the Helsinki Declaration of 1975, as revised in 2000. 
All donors had signed an informed consent form prior to blood donation. Within 30–60 min of blood drawing, 
PBMCs were isolated by centrifugation on Histopaque-1077 (Sigma-Aldrich, Bornem, Belgium) density gradient 
according to the manufacturer’s instructions. Isolated cells were suspended at a density of 106 cells/ml in LGM-3 
culture medium (Lonza, Walkersville, MD, USA) and were allowed to equilibrate to culture conditions at 37 °C 
in a humidified 5% CO2 atmosphere. Two weeks later, the experiment was repeated using fresh PBMCs from the 
same donors, resulting in a total of 60 samples for microarray hybridisation. For quantitative RT-PCR (qRT-PCR) 
validation, blood collected from 5 different donors (1 male and 4 females), from whom informed consent had 
been obtained, was subjected to identical procedures as the samples used for microarray hybridisation, unless 
otherwise indicated. To confirm the results obtained for isolated PBMCs in whole blood samples, blood was 
collected from 3 donors (1 male and 2 females), from whom informed consent had been obtained, in EDTA 
vacutainer tubes, which were then directly used for irradiation.
In vitro irradiation. Cells were irradiated “free-in-air” at 21 °C in a horizontal position with single doses 
of 0.1 and 1.0 Gy of X-rays from a Pantak HF420 RX generator at an air kerma (Kair) rate of 0.26 Gy/min or 
were sham-irradiated. More detailed information on the irradiation setup can be found in the Supplementary 
Methods. Following in vitro irradiation, PBMCs were incubated at 37 °C in a humidified 5% CO2 atmosphere. 
Whole blood samples were incubated on a rocking platform at 37 °C without additional CO2 supply for the indi-
cated time points.
RNA extraction. RNA from irradiated and sham-irradiated PBMC samples was extracted 8 h after irradia-
tion for microarray hybridisation and 8 and 24 h for qRT-PCR validation. RNA from whole blood samples used 
for qRT-PCR validation was extracted 8 and 24 h after irradiation. For RNA isolation from PBMCs, a combined 
approach consisting of the TRIzol® reagent (Invitrogen, Carlsbad, CA, USA) extraction method and purification 
on Qiagen RNeasy columns (Qiagen, Venlo, The Netherlands), was used. More detailed information on the RNA 
extraction procedure can be found in the Supplementary Methods. The QIAamp RNA Blood Mini Kit (Qiagen, 
Venlo, The Netherlands) was used to extract RNA from whole blood samples. The starting quantity of blood was 
1.5 ml per sample. All procedures were performed following the manufacturer’s instructions. RNA concentration 
was measured on a NanoDrop-2000 spectrophotometer (Thermo Scientific, Erembodegem, Belgium) and the 
quality of total RNA samples was assessed using Agilent 2100 Bioanalyser (Agilent Technologies, Santa Clara, 
CA, USA). All samples had a RNA Integrity Number > 8 and were therefore considered as suitable for further 
processing for microarrays and qRT-PCR.
Microarray hybridisation. Gene expression profiling was performed using the GeneChip® Human Gene 
1.0 ST Array (Affymetrix, Santa Clara, CA, USA), which interrogates 28,536 well-annotated genes with 253,002 
distinct probe sets, allowing expression analysis at both gene and exon level. Since each probe corresponds to one 
exon in most of the cases, we refer to probe set-level analysis as exon-level analysis. More detailed information 
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on the microarray hybridisation procedure can be found in the Supplementary Methods. All microarray data 
are available in MIAME compliant format at the ArrayExpress database (www.ebi.ac.uk/arrayexpress) under the 
accession number E-MTAB-3463.
Microarray data analysis. The obtained microarray data were imported into Partek Genomics Suite, ver-
sion 6.6 (Partek Inc., St Louis, MO, USA) as .CEL-files. Probe summarisation and probe set normalisation were 
done using the Robust Multichip Analysis (RMA) algorithm38, which includes background correction, quantile 
normalisation and log2 transformation. Microarray data were analysed both at the level of probe sets and probe 
sets summarised to genes using a three-way ANOVA with dose, gender and batch as factors. Inclusion of batch 
in the model allowed correcting for differences between experiments resulting from different scanning days of 
the microarrays. To correct for multiple testing, we used the false discovery rate (FDR) as described by Benjamini 
and Hochberg39 to adjust p-values (FDR < 0.05). We also performed linear contrasts between two specific groups 
(0.1 Gy vs control and 1.0 Gy vs control) within the context of ANOVA. The coefficients of the levels in the two 
compared groups add up to 0. The computations of p-values are based on Least-squares means, which are the 
means adjusted by other factors. Genes and exons were considered significantly differentially expressed between 
the two groups if adjusted p-values were < 0.05 with no fold change cutoff. Pearson’s correlation coefficient was 
used to assess dose dependence of the gene expression levels. We used the Principal Components Analysis tool of 
the Partek software as an exploratory method to detect groupings in the dataset as well as to spot possible outliers. 
This technique is used to describe the structure of high dimensional data by reducing its dimensionality. It is a 
linear transformation that converts n original variables (genes or exons, in our case) into n new variables, which 
have three important properties: principal components are ordered by the amount of variance explained, they 
are uncorrelated and they explain all variation in the data. PCA was performed at both gene and exon level using 
normalised expression values. The correlation method applied to calculate the dispersion matrix adjusted the data 
to be standardised to a mean of 0 and standard deviation of 1.
Alternative splicing analysis. To predict alternative splicing in irradiated samples compared to controls, 
we used three different methodologies, since it is known that alternative splicing analysis from gene arrays is prone 
to generate false positive results40. First, we performed Alternative Splicing ANOVA in Partek. A FDR-corrected 
p-value of < 0.05 was considered significant for alternative splicing events. To further reduce the number of false 
positives, we excluded the probe sets with log2 value < 3.0 (noise level) in all samples from analysis, except for the 
cases where there was a significant difference in expression of a single exon between the groups (p < 0.05). Next, 
we used two supplementary methods to perform a pairwise comparison of the samples (0.1 Gy vs 0.0 Gy and 
1.0 Gy vs 0.0 Gy) to further increase the reliability of our results. Gene Array Analyzer41 is an on-line tool that uses 
the Splice Index algorithm42 and allows the user to perform more advanced filtering, i.e., removing probe sets that 
are not expressed in at least one group, removing genes (transcript clusters) that are not expressed in both groups, 
discarding probe sets with high potential for cross-hybridisation and those with very large gene-level normalised 
intensities. Software parameters were set to default values, except for the Splice Index cutoff, which was set to 0.5. 
AltAnalyze43 is an open-source software utilising the FIRMA algorithm which is another method for detection 
of alternative splicing44. Software parameters were set to default values, except for the Minimum alternative exon 
score and the Maximum absolute gene-expression change, which were set to 0.5 and 50, respectively.
Positional Gene Enrichment analysis (PGE). The PGE tool45 is available at http://homes.esat.kuleuven.
be/~biouser/pge/. We used default parameters to detect positional enrichment of radiation-responsive genes.
Prediction analysis. The following statistical models were evaluated with regard to their predictive per-
formance and identification of a minimal list of genes and exons capable of discriminating between exposure 
conditions: GLM, RF46 and PAM method47. A more detailed description of these models can be found in the 
Supplementary Methods.
To compare the predictive performance of genes and exons, two versions of the dataset were constructed: 
(a) a version measuring expression changes at the gene level, and (b) a version measuring expression changes at 
the exon level.
Cross-validation was used to assess whether classification models could be constructed to predict the differ-
ent conditions. The original dataset was split into a part for model training (training set) and a part for model 
evaluation (test set), where both sets are disjoint. In our case, the cross-validation had to be executed at the level 
of individuals, since otherwise correlations between different conditions of the same biological sample might 
have led to overoptimistic results. This setting best mimics the true setup where new, unseen biological samples 
need to be classified by the model. A higher number of possible train-test combinations results in a more robust 
assessment of model performance, since higher numbers of models could be averaged. Therefore, we finally used 
2-fold cross-validation for the prediction analyses (Fig. 1).
For model hyperparameters that needed to be tuned (such as the lambda value for GLM or the threshold for 
PAM), an internal cross-validation on the training partition in each cross-validation loop was used. This optimal 
value was subsequently used to train a final model on the training partition in each cross-validation loop, and 
produce results for the test partition in each cross-validation loop.
Performance of the individual models was evaluated by calculating the AUC in which a value of 0.5 corre-
sponds to random prediction behavior and a value of 1 to optimal prediction performance. This is known to be 
a robust estimator of model performance over different model decision thresholds.
To validate our results on an independent publicly available dataset, we retrieved data from Paul and 
Amundson14 (GEO accession number GSE23515), describing a set of 95 samples from 24 individuals of dif-
ferent age, gender and smoking status exposed to different doses of radiation (0.0, 0.1, 0.5 and 2.0 Gy). After 
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pre-processing, probe sets that did not map to gene symbols and probe sets containing more than 25% empty 
values were filtered out. After this filtering step, 23,031 probe sets were kept for further analysis. Subsequently, 
feature importance rankings were derived from classifiers basedon RF and PAM as described above. The overlap 
between the top 100 genes from our study and those from Paul and Amundson was higher based on the RF rank-
ing; therefore, the cross-validation was performed using this model.
The Venny on-line tool48 was used to compare gene lists and create Venn diagrams: http://bioinfogp.cnb.csic.
es/tools/venny/index.html
Reverse transcription and qRT-PCR. The following genes were selected for qRT-PCR validation: DDB2, 
POLH, MDM2, TNFRSF10B, FDXR, ASTN2, NDUFAF6, and PCNA. RNA samples from 5 donors were used for 
cDNA synthesis using the GoScript™ Reverse Transcription System (Promega, Leiden, The Netherlands) with 
random hexamer primers. For each gene, qRT-PCR reactions were run in duplicate using the MESA GREEN® 
qRT-PCR kit (Eurogentec, Seraing, Belgium) on an Applied Biosystems® 7500 Real-Time PCR instrument fol-
lowing the manufacturer’s instructions. To determine the efficiency and specificity of the designed primers, we 
ran a standard curve experiment with melt curve for every primer pair. Primer sequences and reaction efficiencies 
are listed in Supplementary Table S8. qRT-PCR data were analysed by 7500 Software v2.0.6 and Microsoft Excel 
using the Pfaffl method49. The relative amount of transcript of the selected genes was normalised to PGK1 and 
HPRT1 using the geometric mean of these reference genes50. Relative expression levels were tested for statistical 
significance using the paired t-test; p-values of < 0.05 were considered significant. Pearson’s correlation coefficient 
was used to assess dose dependence of the gene expression levels.
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